Quick Answer
RELMADA THERAPEUTICS, INC. reported R&D Expense of $26.88 million for fiscal year 2025.
RELMADA THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $26.88M | -41.8% |
| 2024 | $46.18M | -15.7% |
| 2023 | $54.81M | -51.6% |
| 2022 | $113.32M | +25.1% |
| 2021 | $90.62M | +151.9% |
| 2020 | $35.97M | +357.7% |
| 2019 | $7.86M | +11.9% |
| 2019 | $7.02M | +138.7% |
| 2018 | $2.94M | +127.5% |
| 2017 | $1.29M | -79.2% |
| 2016 | $6.21M | -21.2% |
| 2015 | $7.87M | +50.0% |
| 2013 | $5.25M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.04M | -63.8% | +43.2% |
| June 30, 2025 | $2.82M | -73.7% | -76.4% |
| March 31, 2025 | $11.95M | -10.2% | +7.2% |
| September 30, 2024 | $11.15M | +6.6% | +4.0% |
| June 30, 2024 | $10.72M | -22.0% | -19.4% |
| March 31, 2024 | $13.31M | -16.1% | +27.3% |
| September 30, 2023 | $10.45M | -65.8% | -23.9% |
| June 30, 2023 | $13.74M | -55.6% | -13.4% |
- RELMADA THERAPEUTICS, INC. showed a decrease of -41.8% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, RELMADA THERAPEUTICS, INC.’s r&d expense has grown by 412.1% (from $5.25 million to $26.88 million).
- The most recent figure is from RELMADA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: